Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 ROIV | Healthcare | $39.53 | 7.19M | $28.98B | -82.35 | ― | Strong Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ROIV | Roivant Sciences | 39.53 | 19.24 | 94.83% |
| Name | Price | % Change | |
|---|---|---|---|
| ROIV | $39.53 | +94.83% |
Roivant Sciences Ltd. (($ROIV)) has held its Q2 earnings call. Read on for the main highlights of the call. Roivant Sciences’ earnings call carried a strongly positive tone, led by
Priovant Therapeutics, a Roivant company, announced the publication in JAMA Dermatology of results from the Phase 2 portion of the BEACON study, a randomized, double-blind, placebo-controlled trial evaluating oral brepocitinib
H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Roivant Sciences (ROIV) to $48 from $47 and keeps a Buy rating on the shares. The firm says Lisraya’s
BofA raised the firm’s price target on Roivant Sciences (ROIV) to $42 from $41 and keeps a Neutral rating on the shares, citing higher Lisraya estimates and a higher valuation
Reports Q2 revenue $35.12M, consensus $4.11M. Product revenue, net was $31M for the three months ended September 30, consisting of net product revenue from sales of Lisraya in its first
Roivant Sciences Ltd. (ROIV) is scheduled to report 2nd quarter earnings on 11/09/2026, before the market opens. Regarding Q2 estimates, Wall Street analysts expect Roivant Sciences Ltd. to post earnings
Citi analyst Samantha Semenkow raised the firm’s price target on Roivant Sciences (ROIV) to $56 from $46 and keeps a Buy rating on the shares ahead of the Q3 report.
TD Cowen raised the firm’s price target on Roivant Sciences (ROIV) to $62 from $55 and keeps a Buy rating on the shares after “spectacular” Phase 3 data for brepocitinib
The major averages were higher near noon, supported by upbeat results from SpaceX and Super Micro Computer that revived optimism around AI demand. In addition to the space technology company
Roivant and Priovant Therapeutics announced results from the Phase 3 CLARITY program evaluating brepocitinib in non-infectious uveitis, or NIU. Brepocitinib met the primary endpoint for both the CLARITY-1 and CLARITY-2
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| ROIV | buy | Reiterated | Nov 12, 2026 | |||
| ROIV | buy | Reiterated | Nov 10, 2026 | |||
| ROIV | hold | Reiterated | Nov 9, 2026 | |||
| ROIV | buy | Reiterated | Nov 9, 2026 | |||
| ROIV | buy | Reiterated | Oct 21, 2026 | |||
| ROIV | hold | Downgraded | Oct 12, 2026 | |||
| ROIV | buy | Reiterated | Sep 25, 2026 | |||
| ROIV | buy | Initiated | Sep 17, 2026 | |||
| ROIV | buy | Reiterated | Sep 8, 2026 | |||
| ROIV | buy | Reiterated | Sep 8, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| ROIV | Feb 15, 2027TBA | $28.98B | $-0.29 | $50.56M | -0.81 | -82.35 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
